Search research articles
Contact Us
Filters
Showing results (131-140 of 176) with videos related to
Page
of 18
Sort By:
NPJ Genomic Medicine
|
October 17, 2022
Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone
Hamza Bakhtiar, Kyle T Helzer, Yeonhee Park, et al.
The American Journal of Pathology
|
February 13, 2018
The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients
Karla Esbona, Yanyao Yi, Sandeep Saha, et al.
Seminars in Arthritis and Rheumatism
|
April 4, 2021
One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days
Christie M Bartels, Ann Chodara, Yi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
E Gabriela Chiorean, Jennifer M Porter, Anne E Foster, et al.
Leukemia
|
January 27, 2022
Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in Nras<sup>Q61R/+</sup> mice
Zhi Wen, Remington Finn, Xin Gao, et al.
Molecular and Cellular Biology
|
June 17, 2009
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants
Zhenyun Yang, Takako Kondo, Cara S Voorhorst, et al.
Head & Neck
|
March 20, 2023
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer
Kourtney L Kostecki, Mari Iida, Anne L Wiley, et al.
Investigational New Drugs
|
February 14, 2009
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
Lida Mina, Ian Krop, Robin T Zon, et al.
Neuro-Oncology
|
May 24, 2019
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma
Shuang G Zhao, Menggang Yu, Daniel E Spratt, et al.
Cancer Chemotherapy and Pharmacology
|
May 22, 2012
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53
E Gabriela Chiorean, Sonal Sanghani, Marissa A Schiel, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 176) with videos related to
Sort By:
Page
of 18
NPJ Genomic Medicine
|
October 17, 2022
Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone
Hamza Bakhtiar, Kyle T Helzer, Yeonhee Park, et al.
The American Journal of Pathology
|
February 13, 2018
The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients
Karla Esbona, Yanyao Yi, Sandeep Saha, et al.
Seminars in Arthritis and Rheumatism
|
April 4, 2021
One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days
Christie M Bartels, Ann Chodara, Yi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies
E Gabriela Chiorean, Jennifer M Porter, Anne E Foster, et al.
Leukemia
|
January 27, 2022
Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in Nras<sup>Q61R/+</sup> mice
Zhi Wen, Remington Finn, Xin Gao, et al.
Molecular and Cellular Biology
|
June 17, 2009
Increased c-Jun expression and reduced GATA2 expression promote aberrant monocytic differentiation induced by activating PTPN11 mutants
Zhenyun Yang, Takako Kondo, Cara S Voorhorst, et al.
Head & Neck
|
March 20, 2023
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer
Kourtney L Kostecki, Mari Iida, Anne L Wiley, et al.
Investigational New Drugs
|
February 14, 2009
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen
Lida Mina, Ian Krop, Robin T Zon, et al.
Neuro-Oncology
|
May 24, 2019
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma
Shuang G Zhao, Menggang Yu, Daniel E Spratt, et al.
Cancer Chemotherapy and Pharmacology
|
May 22, 2012
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53
E Gabriela Chiorean, Sonal Sanghani, Marissa A Schiel, et al.
Page
of 18